Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations

Bradley Rockwell, Nitya Dhanaraj, Mark Forsberg, Swati Goel, David Levitz, Ridhi Gupta, Lauren Shapiro, Noah Kornblum, Eric J. Feldman

Blood (2024) 144 (Supplement 1): 3152.

https://doi.org/10.1182/blood-2024-210480

Published: 2024

Journal Articles

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Blood (2024) 144 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2024-201590

Published: 2024

Journal Articles

Metronomic Low-Dose Regimen of Decitabine and Venetoclax Is Safe and Efficacious for Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 6723.

https://doi.org/10.1182/blood-2024-211307

Published: 2024

Journal Articles

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

John Yan, Josette Kamel, Amit Verma, Eric J. Feldman, Dennis L Cooper, Lauren Shapiro, Ridhi Gupta, Nishi Shah, Noah Kornblum, David Levitz, R. Alejandro Sica, Kira Gritsman, Aditi Shastri, Ioannis Mantzaris, Mendel Goldfinger, Marina Konopleva

Blood (2024) 144 (Supplement 1): 5966.

https://doi.org/10.1182/blood-2024-212222

Published: 2024

Journal Articles

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

M Bakri Hammami, Jeevan Shivakumar, Nina Samuel, Rajvi Gor, Mendel Goldfinger, Noah Kornblum, Lauren Shapiro, Aditi Shastri, Ridhi Gupta, David Levitz, Marina Konopleva, Eric J. Feldman, Kira Gritsman, R. Alejandro Sica, Ioannis Mantzaris, Amit Verma, Dennis L Cooper, Nishi Shah

Blood (2024) 144 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2024-208770

Published: 2024

Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2023-185379

Published: 2023

Journal Articles

A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx

Lemchukwu Amaeshi, Alex Sisto, Lauren Laufer, Kateryna Fedorov, Rosmi Mathew, David Levitz, Ioannis Mantzaris, Noah Kornblum, Mendel Goldfinger, Alejandro Sica, Dennis L Cooper, Marina Y. Konopleva, Bruce Rapkin, Amit Verma, Aditi Shastri, Nishi Shah

Blood (2023) 142 (Supplement 1): 7397.

https://doi.org/10.1182/blood-2023-188024

Published: 2023

Journal Articles

Transportation Cost Is a Significant Barrier to Quality Care for Hematologic Malignancy Patients in a Minority-Rich, Socioeconomically Disadvantaged Population

Lauren Laufer, Lemchukwu Amaeshi, Alex Sisto, Kateryna Fedorov, Rosmi Mathew, David Levitz, Ioannis Mantzaris, Noah Kornblum, Mendel Goldfinger, Alejandro Sica, Dennis L Cooper, Marina Y. Konopleva, Bruce Rapkin, Amit Verma, Aditi Shastri, Nishi Shah

Blood (2023) 142 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2023-186867

Published: 2023

Journal Articles

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

Blood (2022) 140 (Supplement 1): 3360–3361.

https://doi.org/10.1182/blood-2022-167849

Published: 2022

Journal Articles

Acute Clinical Syndrome of HLH in Patients with Hematologic Malignancy and EBV Infection

Kateryna Fedorov, David Levitz, Ariel Fromowitz, Irina Murakhovskaya, Amit Verma

Blood (2022) 140 (Supplement 1): 13244–13245.

https://doi.org/10.1182/blood-2022-159315

Published: 2022

Journal Articles

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

David Levitz, Kateryna Fedorov, Kith Pradhan, Lauren C Shapiro, Aditi Shastri, Kira Gritsman, Nishi Shah, Noah Kornblum, R. Alejandro Sica, Ira Braunschweig, Marina Konopleva, Eric J. Feldman, Amit Verma, Ioannis Mantzaris, Yogenthiran Saunthararajah, Mendel Goldfinger

Blood (2022) 140 (Supplement 1): 6218–6219.

https://doi.org/10.1182/blood-2022-170059

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Metronomic Low-Dose Regimen of Decitabine and Venetoclax Is Safe and Efficacious for Chronic Myelomonocytic Leukemia

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx

Transportation Cost Is a Significant Barrier to Quality Care for Hematologic Malignancy Patients in a Minority-Rich, Socioeconomically Disadvantaged Population

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

Acute Clinical Syndrome of HLH in Patients with Hematologic Malignancy and EBV Infection

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

Email alerts

ASH Publications

American Society of Hematology